Literature DB >> 9549643

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.

D E Martin1, M C Chapelsky, B Ilson, D Tenero, S C Boike, N Zariffa, D K Jorkasky.   

Abstract

This was an open-label, parallel group study to compare the pharmacokinetics of multiple oral doses of eprosartan in subjects with normal renal function (Clcr > 80 mL/min; n = 8) and patients with mild (Clcr 60-80 mL/min; n = 8), moderate (Clcr 30-59 mL/min; n = 15), or severe (Clcr < 30 mL/min; n = 3) renal insufficiency. Each subject received oral eprosartan 200 mg twice daily for 6 days and a single dose on day 7. Mean total maximum concentration (Cmax) and area under the concentration-time curve from 0 to 12 hours (AUC0-12) were similar for healthy subjects and those with mild renal impairment, but were an average of 25% to 35% and 51% to 55% greater for patients with moderate and severe renal impairment, respectively, compared with healthy subjects. Mean renal clearance (Clr), which was similar for healthy subjects and patients with mild renal impairment, was decreased an average of 41% and 95% in the groups with moderate and severe renal impairment, respectively, compared with normal subjects. Eprosartan was highly bound to plasma proteins in all groups; however, the unbound fraction was increased approximately two-fold in the group with severe renal impairment. Mean unbound Cmax and AUC0-12 were an average of 53% to 61% and 185% to 210% greater for the patients with moderate and severe renal impairment, respectively, compared with healthy subjects. Headache was the most common adverse experience reported in all subgroups. Eprosartan was safe and well tolerated regardless of degree of renal impairment. Cmax and AUC were increased and renal clearance decreased in patients with moderate to severe renal impairment in comparison to healthy subjects and patients with mild renal impairment. However, based on the moderate renal clearance and known safety profile of eprosartan, it is not necessary to adjust the dose of eprosartan in patients with renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549643     DOI: 10.1002/j.1552-4604.1998.tb04401.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

Review 1.  Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.

Authors:  D A Sica; T W Gehr; A Fernandez
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 2.  Eprosartan.

Authors:  K J McClellan; J A Balfour
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

3.  Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.

Authors:  Maribel Reyes; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2011-05-26       Impact factor: 3.534

4.  Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.

Authors:  Dmytro Khadzhynov; Torsten Slowinski; Ina Lieker; Hans-Hellmut Neumayer; Diego Albrecht; Henk Johan Streefkerk; Sam Rebello; Harm Peters
Journal:  Clin Pharmacokinet       Date:  2012-10-01       Impact factor: 6.447

Review 5.  Eprosartan: a review of its use in the management of hypertension.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

6.  Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.

Authors:  Jaakko Puttonen; Sampo Kantele; Matti Kivikko; Sari Häkkinen; Veli-Pekka Harjola; Petri Koskinen; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Renal handling of angiotensin receptor blockers: clinical relevance.

Authors:  Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

8.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

9.  Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.

Authors:  Sujata Vaidyanathan; Hilde Bigler; ChingMing Yeh; Marie-Noelle Bizot; Hans Armin Dieterich; Dan Howard; William P Dole
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 10.  Eprosartan: a review of its use in hypertension.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.